- Home
- IMRX
as 11-14-2024 2:34pm EST
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 73.2M | IPO Year: | 2021 |
| Target Price: | $12.60 | AVG Volume (30 days): | 369.8K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.91 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.00 - $8.89 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Immuneering Corporation News
IMRX Breaking Stock News: Dive into IMRX Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
Zacks
a month ago
IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug
MT Newswires
a month ago
Immuneering Says Potential Pancreatic Cancer Treatment Gets FDA Orphan Drug Designation
GlobeNewswire
a month ago
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
Simply Wall St.
a month ago
Here's Why We're A Bit Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Situation
Zacks
2 months ago
IMRX Stock Soars on Upbeat Efficacy Data From Pancreatic Cancer Study
MT Newswires
2 months ago
Sector Update: Health Care Stocks Flat to Higher Pre-Bell Friday
Benzinga
2 months ago
Why Is Nanocap Immuneering Stock Trading Higher On Friday?
Compare IMRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMRX Immuneering Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.